Tucatinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HER2-Positive Breast Cancer, Metastatic Colorectal Cancer, Colorectal Cancer, Breast Cancer, Advanced Metastatic Colorectal Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Non-Small Cell Lung Cancer · Phase 2 · investigational in the US

Also approved (1)
EU
  • Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.
Product first approved 2021EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Advanced Metastatic Colorectal Cancer
NCT05253651 · Seagen, a wholly owned subsidiary of Pfizer
2022-10-24 – 2030-07-03 · Colorectal Neoplasms
What this study did
HER2-Positive Breast Cancer
Phase 2/3 (1)
Other / comorbidity
NCT04499924 · Seagen Inc.
2021-03-22 – 2024-04-17 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
What this study did
Phase 2 (30)
Advanced Metastatic Colorectal Cancer
NCT05356897 · Academic and Community Cancer Research United
2023-10-31 – 2024-09-17 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IV Colon Cancer AJCC V8, Stage IV Colorectal Cancer AJCC V8, Stage IV Rectal Cancer AJCC V8
What this study did
Breast Cancer
NCT06157892 · Seagen, a wholly owned subsidiary of Pfizer
2024-05-20 – 2029-07-28 · Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
What this study did
NCT07193394 · Institut Curie
2026-01-31 – 2029-06-08 · Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer
What this study did
NCT05892068 · Memorial Sloan Kettering Cancer Center
2023-05-09 – 2028-05-09 · Metastatic Breast Cancer
What this study did
NCT05748834 · SCRI Development Innovations, LLC
2023-07-24 – 2027-11 · Breast Cancer
What this study did
NCT05323955 · Carey Anders, M.D.
2023-03-23 – 2027-11 · Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
What this study did
NCT05458674 · Criterium, Inc.
2024-01-30 – 2027-08-01 · Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
What this study did
NCT05800275 · UNICANCER
2023-12-18 – 2027-06 · Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer
What this study did
NCT05041842 · UNICANCER
2021-12-17 – 2026-04-30 · Metastatic Breast Cancer With a Isolated Brain Progression
What this study did
NCT05583110 · Spanish Breast Cancer Research Group
2023-03-08 – 2025-05-30 · HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma
What this study did
NCT03501979 · University of Alabama at Birmingham
2019-02-20 – 2021-06-22 · Metastatic Breast Cancer, Leptomeningeal Disease
What this study did
Colorectal Cancer
HER2-Positive Breast Cancer
NCT06439693 · Dana-Farber Cancer Institute
2024-08-08 – 2033-03-30 · Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT05955170 · Institut Curie
2023-12-19 – 2028-12-19 · HER2-positive Breast Cancer
What this study did
NCT04789096 · Breast Cancer Trials, Australia and New Zealand
2023-03-07 – 2026-06-04 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT04539938 · Seagen, a wholly owned subsidiary of Pfizer
2020-12-01 – 2025-03-07 · HER2 Positive Breast Cancer
What this study did
NCT05227131 · MedSIR
2022-05-15 – 2024-10 · Metastatic Breast Cancer, Advanced Breast Cancer, HER2-positive Breast Cancer
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05672524 · Memorial Sloan Kettering Cancer Center
2022-12-30 – 2030-07-31 · Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma, Rectal Cancer
What this study did
NCT05062889 · Gruppo Oncologico del Nord-Ovest
2023-05-17 – 2029-12 · Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
What this study did
NCT05673928 · M.D. Anderson Cancer Center
2023-05-16 – 2029-03-01 · Metastatic Solid Tumor, Brain Metastases
What this study did
NCT02693535 · American Society of Clinical Oncology
2016-03-14 – 2028-12-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT03297606 · Canadian Cancer Trials Group
2018-03-23 – 2027-01-31 · Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
What this study did
NCT04430738 · Seagen, a wholly owned subsidiary of Pfizer
2020-09-15 – 2026-12-31 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
What this study did
NCT04632992 · Genentech, Inc.
2021-01-13 – 2024-02-27 · Advanced Unresectable or Metastatic Solid Malignancy
What this study did
NCT05190445 · Pieris Pharmaceuticals, Inc.
2021-11-01 – 2023-02-01 · HER2-positive Gastric Cancer
What this study did
Phase 1/2 (10)
Breast Cancer
NCT04538742 · AstraZeneca
2020-12-28 – 2030-01-31 · Metastatic Breast Cancer
What this study did
NCT07494448 · MedSIR
2026-07-01 – 2028-05-31 · HER 2 Positive Advanced Breast Cancer, Breast Cancer
What this study did
NCT05230810 · Criterium, Inc.
2022-08-25 – 2026-06-30 · HER2-positive Metastatic Breast Cancer
What this study did
NCT04896320 · Providence Health & Services
2021-12-15 – 2023-06-19 · Breast Cancer Stage IV
What this study did
HER2-Positive Breast Cancer
NCT06686394 · Merck Sharp & Dohme LLC
2025-02-26 – 2032-08-02 · Breast Neoplasms, Breast Cancer
What this study did
NCT05868226 · QuantumLeap Healthcare Collaborative
2023-02-15 – 2031-12-30 · HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
What this study did
NCT05319873 · Jonsson Comprehensive Cancer Center
2022-04-07 – 2028-04-01 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced HER2-Positive Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT04512261 · Reva Basho
2022-06-01 – 2024-06-01 · Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, CNS Disease
What this study did
NCT03054363 · University of Colorado, Denver
2017-11-27 – 2023-02-07 · Breast Cancer
What this study did
NCT05091528 · Silverback Therapeutics
2022-02-08 – 2022-07-07 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
What this study did
Phase 1 (18)
Advanced Metastatic Colorectal Cancer
NCT07318389 · M.D. Anderson Cancer Center
2026-04-22 – 2029-11-14 · Dynamic Tumor Resistance, Metastatic Colorectal Cancer
What this study did
Breast Cancer
NCT06239467 · OnKure, Inc.
2024-02-26 – 2027-08-01 · Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
What this study did
NCT03846583 · Dana-Farber Cancer Institute
2020-06-28 – 2020-09-22 · Breast Cancer
What this study did
NCT01983501 · Seagen Inc.
2014-02-28 – 2020-09-03 · HER2 Positive Breast Cancers
What this study did
NCT02025192 · Seagen Inc.
2013-12-31 – 2020-03-16 · HER2 Positive Metastatic Breast Cancers
What this study did
Colorectal Cancer
NCT05382364 · Pfizer
2022-06-29 – 2026-12-31 · Metastatic HER2+ Advanced Breast Cancer, Breast Neoplasms, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
What this study did
HER2-Positive Breast Cancer
NCT06162559 · The Netherlands Cancer Institute
2023-12-18 – 2036-05 · Breast Cancer
What this study did
NCT05553522 · Baptist Health South Florida
2024-01-29 – 2025-12-17 · Brain Metastases, HER2-positive Breast Cancer
What this study did
NCT01921335 · Dana-Farber Cancer Institute
2013-08 – 2023-12-31 · Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06067776 · Jonathan Riess
2024-01-01 – 2026-11-01 · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT02892123 · Jazz Pharmaceuticals
2016-09-30 – 2024-10-31 · HER2-expressing Cancers
What this study did
NCT03914755 · Seagen Inc.
2019-05-08 – 2019-08-04 · Healthy
What this study did
NCT03722823 · Seagen Inc.
2018-10-10 – 2019-05-07 · Hepatic Impairment
What this study did
NCT03826602 · Seagen Inc.
2019-02-12 – 2019-03-15 · Drug-drug Interaction
What this study did
NCT03777761 · Seagen Inc.
2018-12-06 – 2019-03-11 · Healthy
What this study did
NCT03723395 · Seagen Inc.
2018-09-17 – 2018-12-28 · Drug-drug Interaction
What this study did
NCT03758339 · Cascadian Therapeutics Inc.
2017-12-30 – 2018-01-30 · Healthy
What this study did
NCT00650572 · Seagen Inc.
2008-05 – 2013-03 · Cancer
What this study did
Phase 4 (1)
HER2-Positive Breast Cancer
NCT07768358 · Pfizer
2026-11-06 – 2032-03-13 · HER2-positive Breast Cancer, Cervical Cancer, Biliary Tract Neoplasms, Urothelial Cancer, Advanced Non-Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma (GEC), Colorectal Cancer
What this study did
Early phase / not applicable (1)
Breast Cancer
NCT06983691 · Duke University
2026-08-11 – 2027-03 · HER2+ Metastatic Breast Cancer (MBC)
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2/3 (1)
HER2-Positive Breast Cancer

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Advanced Metastatic Colorectal Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tucatinib: this drugApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
BafisontamabPhase 2Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
PelareorepPhase 2Oncolytic virusTumor cells (oncolytic replication)not yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(26 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tucatinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT05323955 · CT.gov ↗
What to watch
December 2026 (5)
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05800275 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05382364 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT06239467 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06016387 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
2027 (11)
March 2027 (2)
Early phase / not applicableBreast CancerRecruiting
Est. primary completion 2027-03 · NCT06983691 · CT.gov ↗
What to watch
Phase 2Metastatic Solid Tumor, Brain MetastasesRecruiting
Est. primary completion 2027-03-01 · NCT05673928 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2027-04-01 · NCT05319873 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT05458674 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Adenocarcinoma of the Rectum, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, HER2 Positive Rectal Adenocarcinoma …Recruiting
Est. primary completion 2027-07-30 · NCT05672524 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-11 · NCT05748834 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
December 2027 (4)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-19 · NCT05955170 · CT.gov ↗
What to watch
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07494448 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 3Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT05253651 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 3HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2028-01-31 · NCT04457596 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2028-05-09 · NCT05892068 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12-07 · NCT07193394 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 2Breast CancerActive not recruiting
Est. primary completion 2029-07-28 · NCT06157892 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗
What to watch
December 2030 (2)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-12-30 · NCT05868226 · CT.gov ↗
What to watch
2032 (2)
March 2032 (1)
Phase 4Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2032-03-13 · NCT07768358 · CT.gov ↗
What to watch
August 2032 (1)
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2032-08-02 · NCT06686394 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

7 October 2026ApprovalFDA approves TUKYSA with trastuzumab and pertuzumab as first-line maintenance in HER2-positive metastatic breast cancer (HER2CLIMB-05)
US, FDA · Source ↗
October 2026ApprovalFDA updates Boxed Warning on Tucatinib (NDA213411)
US, FDA · FDA · Source ↗